Spots Global Cancer Trial Database for pevonedistat
Every month we try and update this database with for pevonedistat cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | NCT03479268 | B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom... | Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia | NCT04172844 | Acute Myelogeno... | Azacitidine Venetoclax Pevonedistat | 18 Years - | Medical College of Wisconsin | |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | NCT03009240 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult... | Decitabine Laboratory Biom... Pevonedistat Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy | NCT03965689 | Metastatic Lung... Metastatic Lung... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Unresectable Lu... Unresectable Lu... | Carboplatin Paclitaxel Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03745352 | Recurrent Acute... Refractory Acut... | Azacitidine Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | NCT03228186 | Non-small Cell ... | Pevonedistat Docetaxel | 18 Years - | University of Michigan Rogel Cancer Center | |
| Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment | NCT03770260 | Recurrent Multi... Refractory Mult... | Ixazomib Citrat... Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | NCT04175912 | Metastatic Chol... Metastatic Hepa... Stage III Hepat... Stage III Intra... Stage IIIA Hepa... Stage IIIA Intr... Stage IIIB Hepa... Stage IIIB Intr... Stage IV Hepato... Stage IV Intrah... Stage IVA Hepat... Stage IVB Hepat... Unresectable Ch... Unresectable He... Unresectable In... | Carboplatin Paclitaxel Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT03813147 | Acute Myeloid L... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Azacitidine Cytarabine Fludarabine Pho... Methotrexate Pevonedistat Therapeutic Hyd... | 1 Month - 21 Years | National Cancer Institute (NCI) | |
| Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | NCT03319537 | Mesothelioma | pevonedistat Pemetrexed and ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | NCT03479268 | B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom... | Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological... | 18 Years - | City of Hope Medical Center | |
| A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes | NCT04985656 | Myelodysplastic... | Pevonedistat Decitabine Cedazuridine | 18 Years - | Takeda | |
| Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor | NCT04800627 | Locally Advance... Metastatic Mali... Unresectable Ma... | Pembrolizumab Pevonedistat | 18 Years - | M.D. Anderson Cancer Center | |
| Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | NCT04712942 | Acute Myeloid L... Myelodysplastic... Minimal Residua... | Pevonedistat Azacitidine | 18 Years - | University of Leipzig | |
| Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy | NCT04090736 | Leukemia, Myelo... | Pevonedistat Azacitidine | 18 Years - | PETHEMA Foundation | |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | NCT03009240 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult... | Decitabine Laboratory Biom... Pevonedistat Pharmacological... | 18 Years - | City of Hope Medical Center | |
| A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems | NCT03814005 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... Renal Insuffici... Liver Disease Neoplasms | Azacitidine Pevonedistat Docetaxel Paclitaxel Carboplatin | 18 Years - | Takeda | |
| An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | NCT02610777 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | Azacitidine Pevonedistat | 18 Years - | Takeda | |
| A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy | NCT04266795 | Acute Myeloid L... | Pevonedistat Venetoclax Azacitidine | 18 Years - | Takeda | |
| Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | NCT03349281 | Refractory Acut... Relapsed Acute ... | Pevonedistat Vincristine Dexamethasone PEG-asparaginas... Doxorubicin Cytarabine Methotrexate Hydrocortisone | 16 Years - 39 Years | University of Miami | |
| Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes | NCT04484363 | Myelodysplastic... | Pevonedistat Azacitidine | 18 Years - | Takeda | |
| Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | NCT04712942 | Acute Myeloid L... Myelodysplastic... Minimal Residua... | Pevonedistat Azacitidine | 18 Years - | University of Leipzig | |
| Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | NCT03459859 | Acute Myelogeno... AML Advanced Myelod... MDS | Pevonedistat Cytarabine | 18 Years - | University of Miami | |
| Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia | NCT04172844 | Acute Myelogeno... | Azacitidine Venetoclax Pevonedistat | 18 Years - | Medical College of Wisconsin | |
| Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | NCT03268954 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | Azacitidine Pevonedistat | 18 Years - | Takeda | |
| Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma | NCT03323034 | Recurrent Lymph... Recurrent Malig... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Prim... | Irinotecan Pevonedistat Temozolomide | 6 Months - 21 Years | Children's Oncology Group | |
| Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy | NCT04090736 | Leukemia, Myelo... | Pevonedistat Azacitidine | 18 Years - | PETHEMA Foundation | |
| Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT03772925 | Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Belinostat Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy | NCT04266795 | Acute Myeloid L... | Pevonedistat Venetoclax Azacitidine | 18 Years - | Takeda | |
| Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML | NCT03709576 | Acute Myeloid L... | Pevonedistat transplant Azacitidine | 18 Years - 70 Years | Milton S. Hershey Medical Center | |
| A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors | NCT03330106 | Advanced Solid ... | Pevonedistat Docetaxel Carboplatin Paclitaxel | 18 Years - | Takeda | |
| Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | NCT03228186 | Non-small Cell ... | Pevonedistat Docetaxel | 18 Years - | University of Michigan Rogel Cancer Center | |
| Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | NCT03349281 | Refractory Acut... Relapsed Acute ... | Pevonedistat Vincristine Dexamethasone PEG-asparaginas... Doxorubicin Cytarabine Methotrexate Hydrocortisone | 16 Years - 39 Years | University of Miami | |
| A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors | NCT03057366 | Advanced Solid ... | Pevonedistat [14C]-Pevonedis... Docetaxel Carboplatin Paclitaxel | 18 Years - | Takeda | |
| Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | NCT03349281 | Refractory Acut... Relapsed Acute ... | Pevonedistat Vincristine Dexamethasone PEG-asparaginas... Doxorubicin Cytarabine Methotrexate Hydrocortisone | 16 Years - 39 Years | University of Miami | |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy | NCT03965689 | Metastatic Lung... Metastatic Lung... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Unresectable Lu... Unresectable Lu... | Carboplatin Paclitaxel Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT03772925 | Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Belinostat Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | NCT03330821 | Acute Myeloid L... Acute Myeloid L... Therapy-Related... | Cytarabine Idarubicin Laboratory Biom... Pevonedistat Pharmacological... | 18 Years - | University of Southern California | |
| Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | NCT03268954 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | Azacitidine Pevonedistat | 18 Years - | Takeda | |
| A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors | NCT03330106 | Advanced Solid ... | Pevonedistat Docetaxel Carboplatin Paclitaxel | 18 Years - | Takeda |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
